Siglecs, a family of receptor-like lectins, recognize glycoproteins and/or glycolipids containing sialic acid in the extracellular space and transduce intracellular signaling. Recently, researchers uncovered significant contributions of Siglecs in cancer immunity, renewing interest in this family of proteins. Previous extensive studies have defined how Siglecs recognize glycan epitopes (glycotopes). Nevertheless, the biological role of these glycotopes has not been fully evaluated. Recent studies using live cells have begun unraveling the constituents of Siglec ligands. These studies demonstrated that glycoprotein scaffolds (counter-receptors) displaying glycotopes are sometimes just as important as the glycotope itself. These new insights may guide future efforts to develop therapeutic agents to target the Siglec - ligand axis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702521 | PMC |
http://dx.doi.org/10.3389/fimmu.2021.813082 | DOI Listing |
ACS Nano
January 2025
Division of Advanced Nano-Materials, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
Heating techniques have underpinned the progress of the material and manufacturing industries. However, the explosive development of nanomaterials and micro/nanodevices has raised more requirements for the heating technique, including but not limited to high efficiency, low cost, high controllability, good usability, scalability, universality, and eco-friendliness. Carbothermal shock (CTS), a heating technique derived from traditional electrical heating, meets these requirements and is advancing at a high rate.
View Article and Find Full Text PDFJ Acquir Immune Defic Syndr
January 2025
Johns Hopkins University School of Medicine, Department of Gynecology and Obstetrics.
Background: Loss to follow-up to HIV care following delivery puts birthing parents with HIV at higher risk of loss of viral suppression, disease progression, and HIV partner transmission. This study assessed factors associated with retention in postpartum HIV care.
Methods: This is a retrospective cohort study at a single academic medical center and included patients followed from January 2014 to December 2022.
Invest Ophthalmol Vis Sci
January 2025
Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Purpose: Inflammatory processes have been involved in diabetic retinopathy (DR). Interleukin (IL)-17A, a pro-inflammatory cytokine, is associated with DR occurrence and development. However, mechanisms underlying the IL-17A impact on DR need further investigations.
View Article and Find Full Text PDFInvest Ophthalmol Vis Sci
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Purpose: To investigate the 10-year changes in visual function and incidence of visual impairment (VI) in highly myopic eyes.
Methods: This longitudinal study enrolled highly myopic individuals who were followed up for 10 years. All participants underwent detailed ophthalmic examinations at baseline and follow-up visits.
Clin Nucl Med
November 2024
From the Interventional Oncology/Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Background: Radiation segmentectomy (RS) is an alternative potential local curative treatment for selected colorectal liver metastases (CLMs) not amenable to ablation or limited resection.
Purpose: The aim of this study was to evaluate the dosimetric response of low volume CLMs to RS in heavily pretreated patients who are not candidates for resection or percutaneous ablation.
Patients And Methods: This single-center retrospective study evaluated CLMs patients treated with RS (prescribed tumor dose >190 Gy) from 2015 to 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!